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Serine 776 of Ataxin-1 Is Critical
for Polyglutamine-Induced Disease
in SCA1 Transgenic Mice
centration. Often these accumulations appear in the nu-
cleus of neurons and are hence termed intranuclear in-
clusions. However, for some of these proteins, the
accumulations occur in the cytoplasm and/or mem-
brane, as in the cases of SCA2 and SCA6, respectively
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chaperones and components of the ubiquitin protea-Mayo Mail Code 206
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its interactions with other proteins, leading to down-Baylor College of Medicine
stream toxic effects (Cummings et al., 1998; Chai etOne Baylor Plaza
al., 1999; Stenoien et al., 1999). Although length of theHouston, Texas 77030
polyglutamine tract is the major determinant of age of
onset and in some instances disease severity, it be-
comes increasingly clear that neuronal vulnerability and
disease progression are not solely dependent on lengthSummary
of the expanded polyglutamine tract. The many observa-
tions that an expanded polyglutamine peptide isolatedPolyglutamine-induced neurodegeneration in trans-
from the intact protein is much more toxic than whengenic mice carrying the spinocerebellar ataxia type 1
in the host protein argues that sequences outside of(SCA1) gene is modulated by subcellular distribution
the glutamine tract function to dampen the deleteriousof ataxin-1 and by components of the protein folding/
effects of the expanded polyglutamine tract (Wellingtondegradation machinery. Since phosphorylation is a
and Hayden, 2000; Zoghbi and Botas, 2002). A criticalprominent mechanism by which these processes are
role for sequences outside of the glutamine tract in dis-regulated, we examined phosphorylation of ataxin-1
ease pathogenesis has also been suggested from theand found that serine 776 (S776) was phosphorylated.
point that each disease is characterized by the loss ofResidue 776 appeared to affect cellular deposition of
a specific subset of neurons (Orr, 2001). For example,ataxin-1[82Q] in that ataxin-1[82Q]-A776 failed to form
in SCA1, cerebellar Purkinje cells are a prominent sitenuclear inclusions in tissue culture cells. The importance
of pathology (Genis et al., 1995; Robitaille et al., 1995),of S776 for polyglutamine-induced pathogenesis was
and in SBMA, it is the spinal motor neurons that are lostexamined by generating ataxin-1[82Q]-A776 trans-
(Kennedy et al., 1968). In addition, within the SCAs, a
genic mice. These mice expressed ataxin-1[82Q]-
mutant repeat size that causes a juvenile form of SCA1
A776 within Purkinje cell nuclei, yet the ability of
results in an adult onset form of SCA3. Conversely, re-
ataxin-1[82Q]-A776 to induce disease was substan- peat lengths that cause adult onset SCA1 cause juvenile
tially reduced. These studies demonstrate that poly- onset SCA2. This further suggests that elements outside
glutamine tract expansion and localization of ataxin-1 of the polyglutamine tract can influence the course of
to the nucleus of Purkinje cells are not sufficient to disease (Zoghbi, 1996), perhaps through their participa-
induce disease. We suggest that S776 of ataxin-1 also tion in interactions with other proteins.
has a critical role in SCA1 pathogenesis. Toward understanding the processes that modify
SCA1 disease progression, several animal models have
Introduction been established and investigated (Burright et al., 1995;
Fernandez-Funez et al., 2000; Watase et al., 2002). Using
An intriguing group of human neurodegenerative dis- a model of Purkinje cell disease in SCA1 transgenic
eases are those associated with the expansion of a mice, we found that nuclear localization of mutant
CAG trinucleotide repeat that encodes a glutamine tract ataxin-1 is critical for disease to develop (Klement et al.,
within the disease-causing protein (Zoghbi and Orr, 1998). Further examination of the SCA1 mice revealed a
2000; Nakamura et al., 2001). This group of disorders set of genes whose expression is decreased in Purkinje
currently includes spinobulbar muscular atrophy cells prior to the onset of pathology, highlighting the
(SBMA), Huntington’s disease (HD), dentatorubral palli- potential role of transcriptional regulation and/or RNA
doluysian atrophy (DRPLA), and the spinocerebellar stability in pathogenesis (Lin et al., 2000). Analyses of
SCA1 mice also indicate that alterations in protein fold-ataxias (SCA) types 1, 2, 3, 6, 7, and 17. In most of these
ing and degradation pathways modify disease progres-disorders, a pathological hallmark is the presence of
sion. Absence of the E3 ubiquitin ligase encoded by thesubcellular sites of elevated polyglutamine protein con-
Ube3A gene enhances pathology in SCA1 mice (Cum-
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several enhancers and suppressors of the SCA1 pheno-
type (Fernandez-Funez et al., 2000). Among the SCA1
modifiers identified by this screen were genes encoding
components of protein folding and clearance pathways,
as well as genes involved in transcriptional regulation,
RNA binding, and nuclear localization.
Thus, studies utilizing both mouse and fly models
point to nuclear import, gene expression, and protein
folding and clearance as processes that impact on SCA1
pathogenesis. It is likely that the effects of many of
the modifiers would depend on interactions between
ataxin-1 and other proteins that might involve residues
outside of the polyglutamine tract. Protein phosphoryla-
tion is a prominent mechanism by which protein/protein
interactions, including those involving nuclear transport
and degradation, are regulated (Hunter, 2000). To assess
whether phosphorylation has a role in regulating
ataxin-1’s function and pathogenicity, we examined the
phosphorylation status of ataxin-1 and found that the
serine at residue 776 (S776) was a site of phosphoryla-
tion. Importantly, neuronal dysfunction is dramatically
dampened in mice expressing an SCA1 transgene en-
coding ataxin-1 with an expanded polyglutamine tract
in which S776 was replaced by an alanine. These results,
along with those presented in the paper by Chen et al.
(2003 [appearing in Cell]) indicate that phosphorylation
of S776 plays a key role in modulating the ability of
mutant ataxin-1 to induce neurodegeneration by regu-
lating its interactions with other cellular proteins.
Results
Ataxin-1 Is Phosphorylated at Serine 776
Examination of the amino acid sequence of ataxin-1
revealed several possible phosphorylation sites (Banfi
Figure 1. Serine 776 Is a Site of Phosphorylation in Ataxin-1et al., 1994). To assess whether any of these sites are
Numbering of amino acid residues within ataxin-1 is based on aphosphorylated, immune-purified ataxin-1[30Q] from
protein with a polyglutamine tract length of 30 residues.stably transfected CHO cells was subjected to tryptic
(A) Dashed line depicts the location of the NLS identified previouslydigestion followed by HPLC and mass spectrometry.
(Klement et al., 1998). The single phosphopeptide identified by HPLC
This analysis examined 30% of the ataxin-1 primary and mass spectroscopy of ataxin-1[30Q] is designated by the boxed
sequence and revealed a single phosphoserine-con- region. Amino acids are indicated using the single letter code.
(B) Percent incorporation of 33P into ataxin-1[30Q]-A776 comparedtaining peptide spanning residues Arg774 to Arg781 with
to the incorporation of 33P into ataxin-1[30Q]-S776.the site of phosphorylation being the serine at residue
(C) Percent incorporation of 33P into ataxin-1[82Q]-A776 compared776 (Figure 1A). To confirm that S776 is a site of
to the incorporation of 33P into ataxin-1[82Q]-S776.phosphorylation of ataxin-1 in vivo, S776 was mutated
to an alanine. Transfected cells expressing full-length
ataxin-1 with a wild-type glutamine tract and an alanine A776 in spite of its abundant and prominent nuclear
at position 776 (ataxin-1[30Q]-A776) had a 50% reduc- localization (Figure 2B). Nuclear inclusions were de-
tion in the amount of 33P incorporated compared to cells tected in 60% of the cells expressing ataxin-1[82Q]-
expressing ataxin-1[30Q] with a serine (ataxin-1[30Q]- S776, while less than 0.1% of the cells expressing
S776) (Figure 1B). Similar results were obtained using ataxin-1[82Q]-A776 contained inclusions (Figure 2C).
cells expressing ataxin-1[82Q]-S776 or ataxin-1[82Q]- Thus, S776 in ataxin-1 is not critical for its nuclear local-
A776 (Figure 1C). ization in transfected cells but clearly plays a major role
in its potential to accumulate in nuclear inclusions.
Ataxin-1 with a conformation that seems to resist deg-Effects of S776 on Nuclear Localization and Solubility
of Ataxin-1 in Tissue Culture Cells radation typically accumulates in these inclusions and
is insoluble when extracted. To determine if loss of inclu-cDNA constructs encoding full-length ataxin-1[82Q]-
S776 or ataxin-1[82Q]-A776 were used to generate sta- sions in ataxin-1[82Q]-A776 transfected cells affects its
conformation and/or solubility, we prepared protein ex-bly expressing ataxin-1 CHO cells. Cells expressing
ataxin-1[82Q]-S776 contained large nuclear inclusions as tracts from cells expressing either ataxin-1[82Q]-S776
or ataxin-1[82Q]-A776 and quantified the amount of in-has been typically seen when ataxin-1 is overexpressed
in cells (Figure 2A). Surprisingly, few nuclear inclusions soluble ataxin-1. The amount of ataxin-1 in the insoluble
fraction decreased drastically (10-fold) from 5% in cellswere detected in cells overexpressing ataxin-1[82Q]-
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ataxin-1. Figure 3A depicts the immunization and subse-
quent purification scheme utilized to obtain the antibody
designated PN1168. The specificity of PN1168 was veri-
fied by Western blot analyses. Reactivity of PN1168 to
ataxin-1 decreased dramatically upon replacing S776
with an Ala (Figure 3B), and thus this antibody requires
the presence of a Ser at position 776 for it to react with
ataxin-1. Recognition of ataxin-1 by PN1168 was not
affected by replacing the Ser at 780 with an Ala or by
substituting a Thr for the Lys at position 772 (Figure 3B).
However, the recognition of ataxin-1-S776 by PN1168
was decreased substantially by the pretreatment of im-
mune-purified ataxin-1 with phosphatase (Figure 3C).
These results show that PN1168 is specific for a phos-
pho-Ser at position 776 of ataxin-1.
Immunohistochemical analyses of cerebellar sections
from SCA1 transgenic mice were used to assess the
subcellular localization of S776-phosphorylated ataxin-1
in vivo. In both ataxin-1[30Q] and ataxin-1[82Q] trans-
genic mice, Purkinje cell nuclei showed the strongest
pattern of staining for ataxin-1 with the 11750 antibody.
In these mice, ataxin-1 was also readily detected with
the 11750 antibody in the cell bodies and throughout
the dendrites of the Purkinje cells (Figures 4A and 4C).
Reactivity with the phospho-specific antibody PN1168
was also most abundant in the nuclei of Purkinje cells
in both ataxin-1[30Q] and ataxin-1[82Q] transgenic mice
and detectable to a much lesser extent in Purkinje cell
bodies (Figures 4B and 4D). Interestingly, the Purkinje
cell dendrites showed no reactivity with the PN1168
antibody. Cerebellar sections from SCA1 mice express-
ing ataxin-1[82Q]-T772 in which the NLS was mutated
(K772T) were also examined. In this instance,
ataxin-1[82Q]-T772 localized predominantly to the cyto-
plasm of the cell body and throughout the dendritic
tree but was minimally reactive with the phospho-S776-
ataxin-1 antibody (Figures 4E and 4F). Endogenous mu-
rine ataxin-1 was visible in the Purkinje cell nuclei, cellFigure 2. Serine 776 of Ataxin-1 Has a Role in the Formation of
Nuclear Inclusions and Solubility of Ataxin-1[82Q] in Transfected bodies, and dendrites with the 11750 antibody. How-
Tissue Culture Cells ever, endogenous ataxin-1 failed to stain with PN1168
Ataxin-1 distribution was assessed by immunofluorescence using (Figures 4G and 4H) above the background level seen
the ataxin-1 antibody 11750. in cerebellar sections from a Sca1 knockout mouse (Fig-
(A) Presence of ataxin-1 nuclear inclusions in CHO cells expressing ures 4I and 4J).
ataxin-1[82Q]-S776. Scale bar equals 5 m.
Given that nuclear inclusions of mutant ataxin-1 are(B) Absence of nuclear inclusions in CHO cells expressing
a pathological hallmark of SCA1, we examined whetherataxin-1[82Q]-A776.
(C) Percent of ataxin-1[82Q]-S776- or ataxin-1[82Q]-A776-express- ataxin-1[82Q] in nuclear inclusions was reactive with the
ing cells containing one or more nuclear inclusions. phospho-S776-ataxin-1 antibody PN1168. To increase
(D) Western blot with antibody 11750 (Servadio et al., 1995) showing the likelihood of detection, mice homozygous for the
the proportion of ataxin-1[82Q] found in the insoluble fraction versus B05 transgene were examined. At 4 weeks of age, nu-
total ataxin-1 in CHO cells expressing ataxin-1[82Q]-S776 and
clear inclusions were readily detected in Purkinje cellsataxin-1[82Q]-A776. The amount of insoluble ataxin-1[82Q] de-
of B05(tg/tg) mice using the ataxin-1 antibody 11NQ andcreased from 5% of total to 0.5%, respectively.
an anti-ubiquitin antibody (Figures 5A and 5B). These
inclusions also stained with the phospho-S776-ataxin-1expressing ataxin-1[82Q]-S776 to 0.5% in cells express-
antibody (Figure 5C). At this age, the mice begin toing ataxin-1[82Q]-A776 (Figures 2D). The finding of trace
develop dendritic abnormalities and have molecularamounts of ataxin-1[82Q]-A776 in the insoluble fraction
changes based on gene expression study (Clark et al.,argues that it has undergone a conformational change
1997; Lin et al., 2000). However, at 18 weeks of age,and/or its protein-protein interactions are affected, re-
while the nuclear inclusions were large and stained ro-sulting in less accumulation into inclusions.
bustly with the ataxin-1 antibody 11NQ and an anti-
ubiquitin antibody (Figures 5A and 5B), they were notImmunolocalization of Phospho-S776 in SCA1
reactive with the PN1168 antibody (Figure 5C). Thus,Transgenic Mice
with increasing age, nuclear inclusions of ataxin-1[82Q]To examine phospho-S776 ataxin-1 in vivo, we gener-
ated an antibody specific for the phospho-S776 form of lost their ability to be stained by the phospho-S776-
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Figure 3. Generation and Specificity of the Phospho-S776-Ataxin-1 Antibody PN1168
(A) The phospho-S776 ataxin-1 peptide used as the immunogen and strategy by which the antibody PN1168 was column purified from serum.
Serum was first passed over a column to which the unphosphorylated version of the immunogen peptide has been attached. The flowthrough
from this column was subsequently passed over a second column containing the phosphorylated version of the immunogen. Antibodies that
bound to the second column were eluted and designated PN1168.
(B) Western blot analyses of ataxin-1-S776, -A776, -T772, and -A780 expressed in transiently transfected COS1 cells. Upper panel is a Western
blot with PN1168, demonstrating that this antibody reacts with ataxin-1-S776, -T772, and -A780 but not with ataxin-1-A776. The lower panel
is a Western blot using the ataxin-1 antibody 11750, showing the level of ataxin-1 expression in each of the transfected cell populations.
(C) Treatment of immune-purified ataxin-1[82Q] with phosphatase dramatically reduces the amount of ataxin-1 detected with the phospho-
S776-ataxin-1 antibody PN1168 and the amount of 33P-ataxin-1 detected by autoradiography. In contrast, phosphatase treatment has no
effect on the amount of ataxin-1 detected with ataxin-1 antibody 11750.
ataxin-1 antibody, possibly due to dephosphorylation seen in ataxin-1[82Q]-S776 mice from line B05(tg/) (Fig-
ure 6B). Results from two of these lines, A776-1 andor masking of epitope by other proteins in the inclusions.
A776-8, are described in detail.
Expression of the ataxin-1[82Q]-A776 protein was as-Generation of Ataxin-1[82Q]-A776 Transgenic
Mice and Expression of Ataxin-1[82Q]-A776 sessed by immunofluorescence using the ataxin-1 anti-
body 11750 under conditions in which the endogenousA Pcp2-driven ataxin-1[82Q]-A776 transgene (Figure 6A)
was constructed and used to establish transgenic mice murine ataxin-1 was not detected (Skinner et al., 1997).
In 5-week-old tg/ mice, ataxin-1[82Q]-A776-8 was ex-as previously described (Burright et al., 1995). Eight
ataxin-1[82Q]-A776 founders were obtained. Three lines pressed widely in Purkinje cells (Figure 6C) in a fashion
similar to that seen in age-matched ataxin-1[82Q]-(designated A776-1, A776-6, and A776-8) demonstrated
uniform and high levels of transgene expression in Pur- S776(tg/) mice from the B05 line (Figure 6D). Examination
of immunostained cerebellar sections at high power re-kinje cells throughout the cerebellar cortex and therefore
were selected for further characterization. Importantly, vealed that ataxin-1[82Q]-A776-8 localized to the nuclei
of Purkinje cells (Figure 6E). However, in contrast to theNorthern blot analysis revealed that each of these lines
expressed transgene RNA at a level comparable to that widespread presence of nuclear inclusions containing
S776 Is Critical for Ataxin-1-Induced Neurodegeneration
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Figure 4. Phospho-S776-Ataxin-1 Localizes to the Nucleus of Purkinje Cells in SCA1 Transgenic Mice
Total ataxin-1 was detected using antibody 11750 (Servadio et al., 1995) and phospho-S776-ataxin-1 was visualized using antibody PN1168.
The outer molecular layer is indicated by ml, the Purkinje cell body layer by pcl, and the inner granule cell layer by gcl.
(A) The ataxin-1-specific antibody 11750 stains ataxin-1[30Q] throughout the Purkinje cells of A02(tg/) mice. Scale bar equals 30 m.
(B) The phospho-S776-ataxin-1-specific antibody PN1168 stains nuclear ataxin-1[30Q] in Purkinje cells of A02(tg/) mice.
(C) The ataxin-1-specific antibody 11750 stains ataxin-1[82Q] throughout the Purkinje cells of B05(tg/) mice.
(D) The phospho-S776-ataxin-1-specific antibody PN1168 stains nuclear ataxin-1[82Q] in Purkinje cells of B05(tg/) mice.
(E) The ataxin-1-specific antibody 11750 stains dendritic and cytoplasmic ataxin-1[82Q] in Purkinje cells of K772T(tg/) mice.
(F) The phospho-S776-ataxin-1-specific antibody PN1168 does not stain dendritic ataxin-1[82Q] in Purkinje cells of K772T(tg/) mice.
(G) The ataxin-1-specific antibody 11750 stains nuclear endogenous murine ataxin-1 in Purkinje cells of nontransgenic mice.
(H) The phospho-S776-ataxin-1-specific antibody PN1168 does not stain endogenous murine ataxin-1 in Purkinje cells of nontransgenic mice.
(I) The ataxin-1-specific antibody 11750 does not stain Purkinje cells of Sca1/ mice.
(J) The phospho-S776-ataxin-1-specific antibody PN1168 does not stain Purkinje cells of Sca1/ mice.
ataxin-1[82Q]-S776 in 5-week-old B05(tg/tg) animals (Fig- A776 to form inclusions, we examined Purkinje cells
from ataxin-1[82Q]-A776(tg/) mice for deposition of theure 6F), no nuclear inclusions were detectable in Purkinje
cells from 5-week-old ataxin-1[82Q]-A776-8(tg/tg) mice ataxin-1[82Q]-A776 at 18, 27, 37, and 46 weeks of age.
We determined the percentage of Purkinje cells con-(Figure 6E).
To more fully characterize the ability of ataxin-1[82Q]- taining inclusions immunoreactive with the ataxin-1
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Figure 5. Detection of Phospho-S776-
Ataxin-1[82Q] in Nuclear Inclusions De-
creases with Age
Homozygous B05 mice were compared at 4
and 18 weeks of age.
(A) The ataxin-1 antibody 11NQ (Skinner et
al., 1997) stains nuclear inclusions at 4 and
18 weeks of age in B05(tg/tg) mice. Scale bar
equals 10 m.
(B) Ataxin-1 nuclear inclusions in 4- and 18-
week-old B05(tg/tg) mice react with an anti-ubi-
quitin antibody.
(C) The phospho-S776-ataxin-1-specific anti-
body PN1168 stains nuclear inclusions at 4
weeks of age but not at 18 weeks of age in
B05(tg/tg) mice.
11NQ antibody at the primary fissure of each cerebellum haviors, we tested the mice on an accelerating rotarod,
a sensitive assay for ataxia. Hemizygous ataxin-1[82Q]-tested (Figure 6G). Inclusions were detectable in 0.2% of
S776 B05 mice show a deficit in rotarod performancethe Purkinje cells of 18-week-old ataxin-1[82Q]-A776(tg/)
as early as 5 weeks of age (Clark et al., 1997). Figuremice, while in 27-week-old mice, the number of Purkinje
7A shows that at 19 weeks of age, the impairment incells with inclusions increased to 7%. In 37-week-old
rotarod performance of B05(tg/) mice was quite severe.ataxin-1[82Q]-A776(tg/) mice, 18% of the Purkinje cells
In contrast, 19-week-old ataxin-1[82Q]-A776-1 hemizy-analyzed had nuclear inclusions of ataxin-1. In 46-week-
gous mice showed no deficit on the accelerating rotarodold mice, this number was similar: 12% of the Purkinje
and were similar to nontransgenic FVB mice in theircells contained inclusions. The percent of Purkinje cells
performance. We also tested A776-8 hemizygous micewith inclusions slowly increased with age, as in the 56-
between 43 and 46 weeks of age (Figure 7B). Theseweek-old founder animal, 32% of the cells contained
A776-8 mice showed no deficit compared to 1-year-oldinclusions (data not shown). In a 32-week-old homozy-
nontransgenic FVB mice.gous ataxin-1[82Q]-A776 mouse, 16% of the Purkinje
Similarly, cerebellar sections from ataxin-1[82Q]-cells contained detectable inclusions (data not shown).
A776-1(tg/), ataxin-1[82Q]-A776-8(tg/), and ataxin-In contrast, 50% of B05(tg/) Purkinje cells in 18-week-
1[82Q]-S776(tg/) B05 mice were examined at 18, 27, andold mice were found to have ataxin-1 nuclear inclusions,
37 weeks of age (Figure 7C). By calbindin immunofluo-while 100% of the Purkinje cells in 27- and 37-week-old
rescence, Purkinje cell morphology in 18-week-oldB05(tg/) mice contained inclusions (Figure 6G). Thus,
ataxin-1[82Q]-A776(tg/) mice was identical to that ofreplacing the Ser with an Ala at position 776 in
wild-type mice, showing no signs of dendritic thinningataxin-1[82Q] substantially reduced the rate at which
or Purkinje cell heterotopia. Importantly, at this age thenuclear inclusions were formed, in vivo, in SCA1 trans-
B05 hemizygous mice showed marked Purkinje cell pa-genic Purkinje cells.
thology including considerable dendritic atrophy and
several heterotopic Purkinje cell bodies. Similarly, at 27
Neurological Phenotype and Neuropathology weeks of age, the morphology of Purkinje cells in the
of Ataxin-1[82Q]-A776 Mice A776(tg/) mice was unremarkable. This was in stark con-
At all ages examined, the ataxin-1[82Q]-A776(tg/) mice trast to the severe atrophy of the Purkinje cell dendrites
were indistinguishable from their wild-type littermates and disruption of the Purkinje cell layer seen in a 27-
in home cage behavior. So far, the ataxin-1[82Q]-A776 week-old B05(tg/) mouse.
hemizygous mice have been evaluated up to 1 year of By 37 weeks of age, some sign of dendritic atrophy
age. This is an age well past the age of 12 weeks when was apparent in the ataxin-1[82Q]-A776(tg/) mice (Figure
B05 hemizygous mice show signs of ataxia in home 7C). The thickness of the molecular layer was reduced
cage behavior (Clark et al., 1997). To insure that the lack by 30% compared to wild-type mice. However, in the
of phenotype in ataxin-1[82Q]-A776 mice is not due to 37-week-old ataxin-1[82Q]-A776 hemizygous mice, the
slightly lower ataxin-1 levels compared to the B05 mice, organization of the Purkinje cell body layer remained
we bred the A776 transgenics to homozygosity. These intact and no signs of Purkinje cell loss were detected.
A776(tg/tg) mice, which express at least 25% more trans- Similarly, in a 46-week-old A776-8(tg/) mouse, the Pur-
gene RNA than the B05(tg/) animals, have been carried kinje cell body layer remained intact with only modest
out to 36 weeks of age and, like the ataxin-1[82Q]-A776 thinning of the molecular layer. In contrast, Purkinje cell
hemizygous mice, the A776 homozygous animals pathology was very severe in 37-week-old B05(tg/) mice.
showed no signs of ataxia by home cage behavior. Atrophy of the dendritic tree was essentially complete
To uncover subtle coordination deficits that could be and disorganization of the Purkinje cell layer was exten-
sive. At 32 weeks of age, moderate signs of Purkinjemissed by looking for ataxic gait in the home cage be-
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Figure 6. Ataxin-1[82Q]-A776 Localizes to
the Nucleus and Has a Reduced Rate of Nu-
clear Inclusion Formation in Transgenic Mice
(A) Diagram of the Pcp2-ataxin-1[82Q]-A776
transgene. Transgene expression was driven
by the Purkinje cell-specific Pcp2 regulatory
element.
(B) Relative amount of transgene expression
in the three lines of Pcp2-ataxin-1[82Q]-A776
transgenic mice. mRNA levels were normal-
ized to the level of transgene mRNA in B05(tg/)
mice.
(C) Expression of ataxin-1[82Q]-A776 in a
5-week-old A776-8(tg/) animal. Scale bar
equals 100 m.
(D) Expression of ataxin-1[82Q]-S776 in a
5-week-old B05(tg/) animal.
(E) Ataxin-1[82Q]-A776 is expressed uni-
formly throughout the nucleus in Purkinje
cells in a 5-week-old A776-8(tg/tg) animal. Scale
bar equals 10 m.
(F) Ataxin-1[82Q]-S776 forms nuclear inclu-
sions in a 5-week-old B05(tg/tg) mouse.
(G) Comparison of the frequency of nuclear
inclusions in transgenic Purkinje cells ex-
pressing ataxin-1[82Q]-S776 with the fre-
quency of nuclear inclusions in ataxin-
1[82Q]-A776-expressing Purkinje cells. The
frequency of nuclear inclusions was deter-
mined in B05(tg/) mice at 18, 27, and 37 weeks
of age. For the B05 mice, at 18 weeks, 345
Purkinje cells from two mice were analyzed;
at 27 weeks, 272 Purkinje cells from two mice
were assessed; and at 37 weeks, 100 Purkinje
cells from one mouse were analyzed for the
presence of inclusions. The dashed portion
of the B05 line indicates that inclusions con-
tinue to be in 100% of the Purkinje cells after
37 weeks. The frequency of nuclear inclu-
sions was determined in A776(tg/) mice (lines
1 and 8) at 18, 27, 37, and 46 weeks of age.
The mean and standard error of the mean are
given for each time point. At 18 weeks, 438
Purkinje cells from three mice were assessed;
at 27 weeks, 387 Purkinje cells from three mice
were analyzed; at 37 weeks, 464 cells from
three mice were screened; and at 46 weeks,
359 Purkinje cells from three A776 mice were
counted for inclusions.
cell pathology were detected in sections examined from mutational mechanism, however, a central issue has
an A776 homozygous mouse. Thus, increasing the ex- been discovering the molecular mediator of toxicity in
pression of the A776 transgene to a level above that this class of disease: is it the expanded polyglutamine
seen in B05(tg/) resulted in the appearance of Purkinje tract per se, is it the expanded tract within the host
cell pathology. However, the severity of pathology in the protein, or is it the host protein, which becomes particu-
32-week-old A776tg/tg mouse was considerably less than larly toxic due to an altered conformation engendered
that seen in B05tg/ mice at 27 weeks or 18 weeks of by the expanded tract?
age (Clark et al., 1997). Studies in cell culture, invertebrate, and mouse mod-
els have clearly shown that a polyglutamine peptide is
quite toxic to cells and causes progressive phenotypesDiscussion
and cell death. Yet, there is evidence suggesting that
host protein sequences, outside of the glutamine tract,Expansion of a glutamine tract is clearly the initiating
impact on the course of disease. A polyglutamine pep-event in the pathogenesis of polyglutamine neurodegen-
erative disorders like SCA1. Since the discovery of this tide is often much more toxic than one flanked by se-
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Figure 7. Ataxin-1[82Q]-A776 Is Substantially Less Pathogenic in Transgenic Mice
(A) Rotarod performance of A776-1(tg/) mice at 19 weeks of age is indistinguishable from nontransgenic littermates and dramatically increased
compared to age-matched B05(tg/) mice (Clark et al., 1997). The mean and standard error of the mean are represented for each trial day for
the animals tested.
(B) Rotarod performance of A776-8(tg/) mice at 43–46 weeks of age is indistinguishable from 1-year-old nontransgenic mice in contrast to the
inability of 1-year-old B05(tg/) mice to perform the task (Clark et al., 1997).
(C) Assessment of Purkinje cell morphology by calbindin immunofluorescence. Mice from two lines expressing ataxin-1[82Q]-A776 (A776-1
and A776-8) or ataxin-1[82Q]-S776 were analyzed between 17 and 37 weeks of age. In addition, a 46-week-old A776-8(tg/), a 32-week-old
A776-8(tg/tg), and a 52-week-old nontransgenic were also analyzed. Scale bar equals 100 m.
quences from the host protein (Wellington and Hayden, ing features. Pathologically, HD is characterized by cell
loss in the cortex and striatum. In contrast, in SCA1,2000; Zoghbi and Botas, 2002). The importance of the
flanking peptide sequence in modulating polyglutamine the presenting clinical features are loss of balance and
slurred speech resulting from cerebellar dysfunctiontoxicity is highlighted by data from both human and
mouse studies. Each of the polyglutamine disorders is and Purkinje cell pathology. In SCA7, retinal dysfunction
and visual loss occur in addition to cerebellar diseasecharacterized by a specific set of neurological and
pathological alterations. For example, in Huntington’s (Stevanin et al., 2000). Moreover, within the SCAs, there
is a dramatic difference in the effect of repeat expansiondisease, jerky body movements, chorea, and psycholog-
ical changes such as depression are the usual present- on disease course. Repeat sizes that lead to late onset
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disease in SCA3 cause a juvenile onset disease in SCA1. degradation pathway (Cummings et al., 1998). Inhibition
of the proteasome aggravates the frequency and sizeThe findings argue that the expanded repeat tract is not
the sole factor that induces pathology and determines of nuclear aggregates and decreases the amount of
ataxin-1 in the soluble fraction of protein extracts. Thus,disease severity. These findings, however, do not distin-
guish whether flanking sequence simply modulates the the disappearance of nuclear inclusions may imply bet-
ter cellular handling of ataxin-1[82Q]-A776. Consistentglutamine tract toxicity or whether the host protein itself
may become toxic upon glutamine expansion. In this with this is the fact that we found only 0.5% of ataxin-
1[82Q]-A776 in the insoluble fraction of extracts fromstudy, we set out to evaluate ataxin-1’s phosphorylation
in order to gain insight about how such modification transfected cells, in contrast to ataxin-1[82Q]-S776,
where 5% of the protein was in the insoluble fraction.may impact pathogenesis.
However, in Purkinje cells, the relationship between
ataxin-1[82Q] solubility and inclusion formation is moreS776 in Ataxin-1 Is Phosphorylated and Modulates
complex. In Purkinje cells, ataxin-1[82Q]-A776 formedAtaxin-1’s Ability to Form Nuclear Inclusions
inclusions to a considerably less extent than didUsing tryptic digestion followed by HPLC and mass
ataxin-1[82Q]-S776, yet neither form of ataxin-1[82Q] isspectrometry, we found that ataxin-1 is phosphorylated
detectable by Western blot analysis of cerebellar ex-at serine 776. An antibody, PN1168, generated using an
tracts (Burright et al., 1995, and data not shown).ataxin-1 peptide spanning a phosphorylated serine at
position 776, recognized phosphorylated ataxin-1 in
vivo, both in transfected cells and transgenic mice. The Serine at Position 776 Is Critical
for Ataxin-1[82Q] PathogenicityImmunofluorescence and immunohistochemical
studies revealed that by using the phospho-S776- To test whether our observations in cell culture would
also hold in vivo and to determine if the pathogenicataxin-1-specific antibody PN1168 both in transgenic
mice expressing a wild-type SCA1 allele (A02(tg/) mice) effects of ataxin-1[82Q] require a serine at position 776,
we generated several lines of transgenic mice that ex-and in mice expressing a disease-causing mutant SCA1
allele (B05(tg/) animals), S776-phosphorylated ataxin-1 press ataxin-1[82Q]-A776 in cerebellar Purkinje cells.
Three lines of mice expressed the transgene at levelslocalized primarily to the nucleus. Cytoplasmic ataxin-1
stained much less robustly with the phospho-S776- comparable to those seen in B05(tg/) mice that express
an allele that encodes for ataxin-1[82Q]-S776. Mice fromataxin-1-specific antibody. The relative decrease in
staining with the phospho-S776 antibody compared to all three lines did not show any signs of neurological
dysfunction as evident by normal rotarod behaviortotal ataxin-1 was particularly noticeable in Purkinje
cells of SCA1 mice expressing ataxin-1[82Q]-T772. In tested at 19 weeks and 43 to 46 weeks and by monitoring
their home cage behavior up to 1 year of age. Thesethese mice, the NLS of ataxin-1 is mutated and ataxin-1
is localized largely to the cytoplasm of the cell body ages are well beyond the ages at which the B05(tg/)
mice develop an altered neurological phenotype, whichand throughout the dendritic tree. Interestingly, in COS1
cells transfected with ataxin-1[82Q]-T772, a greater pro- usually includes impaired performance on the rotarod
at 5 weeks of age and gait ataxia observed in homeportion of ataxin-1 localizes to the nucleus than localizes
to nuclei of transgenic Purkinje cells (Klement et al., cages by 12 weeks of age. Thus, having a serine at
position 776 is critical for the polyglutamine-induced1998). Thus, the considerable reactivity of ataxin-
1[82Q]-T772 with the phospho-S776 antibody PN1168 disease to manifest itself. Lastly, because ataxin-
1[82Q]-A776 localized to the nuclei of Purkinje cells, justseen in Western blots of COS1 extracts likely represents
nuclear ataxin-1. These data indicate that the phosphor- like the protein with S776, the decrease in toxicity seen
with A776 protein cannot be explained by a decreaseylation of ataxin-1 at S776 is linked to its transport into
the nucleus of Purkinje cells. in its localization in the nucleus. How might a serine at
position 776 affect the toxicity of ataxin-1[82Q]?However, transport of ataxin-1 to the nucleus is not
dependent on it being phosphorylated at S776 because In the ataxin-1[82Q]-A776 transgenic mice, the protein
did not accumulate in nuclear inclusions in a manneran Ala at position 776 did not prevent nuclear localiza-
tion of full-length ataxin-1[82Q] in cell culture and in similar to what has been observed in the B05 mice. Does
this mean that the inclusions are required for disease?Purkinje cells of transgenic mice (see below). Intrigu-
ingly, ataxin-1 in the dendritic tree of Purkinje cells, while We argue that this is not the case. While the presence
of protein inclusions is a pathological hallmark of SCA1readily staining with the ataxin-1 antibody 11750, failed
to react with the phospho-specific antibody PN1168 and most other polyglutamine diseases (Ross, 1997),
the relationship between these entities and disease is(Figure 4), indicating that phosphorylated ataxin-1 at
S776 might be excluded from the dendritic tree in Pur- complex (Kim and Tanzi, 1998; Sisodia, 1998). At this
time it is possible to make several statements about thiskinje cells.
An intriguing finding was the pattern of the nuclear relationship with a reasonable level of certainty. (1) The
ability of mutant ataxin-1 to induce disease in cerebellardeposition of ataxin-1[82Q]-A776. Overexpression of
ataxin-1[82Q]-S776 revealed nuclear accumulation of Purkinje cells is not dependent on the formation of nu-
clear inclusions (Klement et al., 1998; Cummings et al.,the protein in inclusions (Figure 2A). In contrast,
ataxin-1[82Q]-A776 was diffusely distributed in nuclei 1999; Watase et al., 2002). (2) The presence of inclusions
is exacerbated by interfering with proteasomal degrada-of transfected cells and was not found in inclusions
(Figure 2B). Nuclear inclusion formation in cells trans- tion and by overexpressing mutant ataxin-1 in cells,
mice, and flies (Zoghbi and Botas, 2002). Thus, accumu-fected with ataxin-1 is typically dependent on length of
glutamine tract and integrity of ubiquitin-proteasome lation of ataxin-1 in nuclear inclusions very likely reflects
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that some of this protein is not efficiently degraded and
becomes sequestered in these inclusions. (3) Inclusion
formation also seems to be dependent on several cellu-
lar processes (such as nuclear import, ubiquitination,
and protein-protein interaction), and interfering with any
of these processes can disrupt inclusion formation. The
manner in which such a disruption affects disease is
likely dependent on where in the pathway leading to
inclusion formation one intercedes. For example, in-
terfering with cellular processes that might sequester
the protein in preparation for degradation, e.g., Ube3A
(Cummings et al., 1999), would aggravate disease. In
contrast, disrupting the ability of ataxin-1 to interact with
cellular proteins involved in both inclusion formation and
pathogenesis would ameliorate disease, e.g., the A776
substitution described in this study. (4) In a murine
knockin model of SCA1 where mutant ataxin-1 is not
overexpressed, the increased vulnerability of Purkinje
cells that are the last to sequester the protein into inclu-
sions suggest that cellular factors involved in some of
the processes aimed at handling the mutant protein may
be limiting (Watase et al., 2002).
Studies by Chen and colleagues (2003 [appearing in
Cell]) demonstrated that S776 is critical for the interac-
tion of ataxin-1 with 14-3-3 and that 14-3-3 enhanced
the steady-state levels of ataxin-1[82Q]-S776 in tissue
culture cells and in an SCA1 Drosophila model. In con-
trast, 14-3-3 had no effect on the level of ataxin-1[82Q]-
A776. These data together with our findings that
ataxin-1[82Q]-A776 mice are resistant to polyglutamine-
induced pathology point to the critical role of S776 in
pathogenesis and to the importance of protein-protein
Figure 8. A Model Depicting that Conformation Alterations in
interactions mediated via this serine. Based on the data Ataxin-1 Caused by the Expanded Polyglutamine Tract as well as
presented here and on those presented by Chen et al. Phosphorylation of S776 Are Important for the Development of
(2003), we propose that at least two structural features Disease
of ataxin-1[82Q] must be in place for disease to develop (A) Expansion of the polyglutamine tract leads to a conformation
change in the protein. This change along with the phosphorylation(Figure 8). Clearly, expansion of the polyglutamine tract
of serine 776 of ataxin-1 alters the conformation of ataxin-1 thatto a length within the mutant range must occur. There
subsequently might affect its interaction with other proteins. Theseis considerable data indicating that this expansion re-
processes are involved in both the formation of inclusions and thesults in the misfolding of the protein. We suggest that
development of disease.
this effect may cause the protein to be in an alternate (B) Mutation of serine 776 to alanine prevents the phosphorylation
or intermediate-folding state that may favor protein-pro- of this residue, perhaps blocking phosphorylation and the conforma-
tein interactions and/or somewhat resist degradation. tion change induced by this modification of ataxin-1. The result is
a dramatic dampening of disease progression and slowing inclusionIn support of this hypothesis is the finding that overex-
formation as indicated by the dashed lines.pression of wild-type ataxin-1 can lead to similar effects,
albeit milder, than the protein with an expanded gluta-
glutamine tract highlights the importance of studyingmine tract (Fernandez-Funez et al., 2000). This suggests
the effect of the glutamine expansion in the context ofthat some wild-type ataxin-1 molecules might take on
the full-length protein. We showed that S776 is a site ofthe alternate folded state favored by the repeat expan-
phosphorylation, and Chen et al. (2003) demonstratedsion. Second, the surprising new insight from this cur-
that phosphorylation of S776 was required for ataxin-1rent study is the finding that, although the N-terminal
to interact with the protein 14-3-3 and that this interac-polyglutamine tract is critical for pathogenesis, it is not
tion exacerbated neurodegeneration in a fly model ofsufficient, even when the protein is in the nucleus. Thus,
SCA1. These data demonstrate that host protein se-protein/protein interactions in the nucleus that involve
quences outside of the glutamine tract through interac-only the expanded polyglutamine tract (Waragai et al.,
tions with a protein like 14-3-3 have a critical role in1999; Okazawa et al., 2002) are unlikely to be sufficient
the accumulation and pathogenicity of a polyglutaminefor disease. In the case of ataxin-1, molecular events
protein. The extent to which the interacting proteinscentered on S776 in the C terminus of ataxin-1[82Q] are
that direct inclusion formation overlap with those thatalso critical for pathogenesis.
mediate pathogenesis remains to be determined.The finding that ataxin-1[82Q]-A776 forms nuclear in-
clusions in Purkinje cells at a rate considerably slower
Experimental Proceduresthat ataxin-1[82Q]-S776 argues that an expanded poly-
glutamine tract can be efficiently handled by the protein Constructs
degradation machinery. The dramatic reduction in Plasmids for transient transfection experiments were constructed
by placing the ataxin-1 cDNA into the eukaryotic expression vectorpathogenicity of ataxin-1[82Q]-A776 in spite of its long
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pCDNA1amp (Skinner et al., 1997). To change the amino acid at ment were assessed for the presence of inclusions. Lysates from
CHO cells growing on 60 mm cell culture plates expressing eitherposition 776, the QuickChange site-directed mutagenesis kit (Stra-
tagene) was utilized. FLAG-tagged pCDNA-ataxin-1[30Q] or S776-ataxin-1[82Q] or A776-ataxin-1[82Q] were used to separate
insoluble from soluble ataxin-1. The cells were lysed in 450 l RIPApCDNA-ataxin-1[82Q] was used as the PCR template (Skinner et
al., 1997). Using a mammalian codon frequency table, we changed buffer (150 mM NaCl, 1% SDS, 1% Triton X-100, 50 mM Tris-Cl [pH
7.5], 100 g/ml PMSF) for 45 min on ice. DNA in the lysate wasthe serine codon (UCG) to alanine (GCC). The ataxin-1 A776 trans-
gene was generated by replacing the BstEII-NarI fragment from PS- sheared as described above. A fraction of the lysate (150 l) was
removed to be used to determine total ataxin-1 expression. The82 (Burright et al., 1995) with the BstEII-NarI fragment from the
pCDNA-ataxin-1-A776-[82Q] mammalian expression vector de- remainder of the lysate was centrifuged at 16,000  g for 15 min
at 4C and separated into soluble (supernatant) and insoluble (pellet)scribed above. The sequence and the polyglutamine tract length of
all constructs were confirmed by sequencing. fractions. Prior to PAGE, the insoluble fraction was solubilized in
300 l of 1 SDS sample buffer. Western blot analysis was per-
formed and probed with anti-ataxin-1 11750 as described above.Generation of Cell Lines Stably Expressing Ataxin-1
The SCA1 cDNAs from pCDNA-ataxin-1[82Q]-S776 and pCDNA-
ataxin-1[82Q]-A776 were subcloned into pTRE (Clontech). The Analysis of Ataxin-1 Phosphorylation in Tissue Culture Cells
pTRE-SCA1 plasmids were cotransfected with pTK-Hyg into the Analysis of ataxin-1 phosphorylation was performed in transiently
CHO-AA8 Tet-off cell line (Clontech). Stable cell lines were isolated transfected COS1 cells expressing ataxin-1 with either 30 or 82
by selection in hygromycin. Hygromycin-resistant clones were re- glutamine repeats. Thirty-six hours posttransfection, the cells were
cloned and screened for ataxin-1 expression by Western blotting labeled for 7 hr with 33P-orthophosphate (ICN) at a concentration of
and immunofluorescence. 750 Ci/ml. Following labeling, the cells were washed two times
with PBS and lysed in 0.5 ml lysis buffer (50 mM Tris-Cl [pH 7.5], 2.5
mM MgCl2, 100 mM NaCl, 0.5% Triton X-100, 1 protease inhibitorsMass Spectroscopy Analysis
[Roche Biochemicals], phosphatase inhibitor cocktails I and IIAtaxin-1[30Q] was immunoprecipitated from stably transfected CHO
[Sigma]). The cells were lysed on the plates by rocking at 4C oncells using the ataxin-1 antibody 11NQ (Skinner et al., 1997). Cells
ice for 15 min. The DNA in the lysate was sheared by passing the(20 106) were lysed in 0.25 M Tris-Cl (pH 7.5) containing 1 prote-
lysate through a 21-gauge syringe ten times followed by a 25-gaugease inhibitors (Roche Biochemicals) and phosphatase inhibitor
syringe five times. The lysate was cleared by centrifugation at 14,000cocktails I and II (Sigma) by three cycles of freeze-thawing. The
rpm for 10 min at 4C. Ataxin-1 was immunoprecipitated from the11NQ antibody was added to the lysate and was incubated at 4C
lysate using the ataxin-1 antibody 11750 by incubation with rotationwith rotation overnight. Immune complexes were collected by incu-
overnight at 4C. The ataxin-1 immune complexes were capturedbation for 1 hr with protein G sepharose beads (Amersham Phar-
by the addition of washed protein-G sepharose beads (Amershammacia Biotech). Following incubation, the complexes were collected
Pharmacia Biotech) by incubation with rotation for 4 hr at 4C. Theby centrifugation at 2500 rpm for 4 min at 4C and washed four
immune precipitates were collected by centrifugation, washed threetimes in RIPA buffer (50 mM Tris-Cl [pH 8.0], 150 mM NaCl, 1%
times with lysis buffer, and resuspended in 2 SDS sample loadingNP40, 0.5% deoxycholate, 0.1% SDS). Beads were resuspended
buffer. Boiled samples were loaded onto a 3%–8% Tris-Acetatein 2 SDS sample buffer, boiled, and run on a 4%–12% Bis-Tris
polyacrylamide gel (Invitrogen). Following electrophoresis, proteinsacrylamide gel (Invitrogen). Following electrophoresis, the gel was
were transferred to a nitrocellulose membrane (Protran, Schleicherstained for 15 min with Coomassie and washed with ultrapure water
and Schuell). The membrane was subjected to autoradiography tofor 60 min. To quantify the amount of purified protein, the intensity
determine the amount of 33P incorporation. Following autoradiogra-of the ataxin-1 bands were compared with the intensity of the known
phy, the membrane was subjected to Western blot analysis usingconcentrations (0.1 g, 0.2g, 0.5 g, and 1 g) of the 100 kDa band
the anti-polyglutamine antibody 1C2 (Chemicon) to normalize forof the BenchMark protein ladder (Invitrogen). Ataxin-1-containing
the amount of ataxin-1 in each sample. In the case of ataxin-1 withbands that had an intensity of at least 0.1 g per band were excised
30 glutamines, we probed the membrane with anti-ataxin-1 11750and stored at20C. We repeated the immunoprecipitation protocol
(Servadio et al., 1995).and pooled approximately 50 g immune-purified ataxin-1. Tryptic
digestion and sequence analysis was performed at the Harvard
Microchemistry Facility. This analysis consisted of microcapillary Characterization of an Ataxin-1 S776 Phospho-Specific
reverse-phase HPLC nano-electrospray tandem mass spectrometry Antibody (PN1168)
on a Finnigan LCQ quadruple ion trap mass spectrometer. The ataxin-1 S776 phospho-specific antibody was generated and
affinity purified by New England Peptide (Fitchburg, MA). Briefly,
the S776 phosphorylated peptide (see Figure 3) was used to immu-Cell Transfections, Protein Analysis,
and Immunofluorescence nize two rabbits. Serum collected from these rabbits was passed
over an affinity column that had the unphosphorylated form of theCOS1 cells growing on 60 mm dishes were transiently transfected
using Effectene (Qiagen) as per the manufacturer’s recommended immunizing peptide bound to the matrix. The flowthrough from this
column was passed over a second column that had the phosphory-protocol. Forty-eight hours posttransfection, cells were washed in
PBS and lysed in 0.5 ml lysis buffer (50 mM Tris-Cl [pH 7.5], 2.5 mM lated immunizing peptide bound to the matrix. The eluent from this
column was designated antibody PN1168.MgCl2, 100 mM NaCl, 0.5% Triton X-100, 1 protease inhibitors
[Roche Biochemicals], phosphatase inhibitor cocktails I and II The specificity of PN1168 was assessed by treating immunopre-
cipitated ataxin-1 with shrimp alkaline phosphatase (USB). COS1[Sigma]). The cells were lysed on the plates by rocking at 4C on
ice for 15 min. The DNA in the lysate was sheared by passing the cells were transiently transfected with pCDNA-ataxin-1[82Q] and
labeled with 33P-orthophosphate and immunoprecipitated as de-lysate through a 21-gauge syringe ten times followed by a 25-gauge
syringe five times. The lysate was cleared by centrifugation at 14,000 scribed above using 500 l lysis buffer (50 mM Tris-Cl [pH 7.5], 2.5
mM MgCl2, 100 mM NaCl, 0.5% Triton X-100, 1 protease inhibitorsrpm for 10 min at 4C. The protein concentration was determined
using protein assay dye reagent (Bio-Rad). Twenty micrograms of [Roche Biochemicals], phosphatase inhibitor cocktails I and II
[Sigma]). Following incubation with the protein-G sepharose beads,protein was loaded in duplicate wells of a 3%–8% Tris-acetate poly-
acrylamide gel (Invitrogen) and transferred to nitrocellulose mem- the immunoprecipitate was washed two times with lysis buffer fol-
lowed by two washes with phosphatase buffer (20 mM Tris-Cl [pHbrane (Protran, Schleicher and Schuell). One membrane was probed
with anti-ataxin-1 (11750, 1:5000) and the other with anti-S776 phos- 8.0], 10 mM MgCl2). The immunoprecipitate was divided into two
equal portions; one half was untreated while the other half wasphorylated ataxin-1 (PN1168, 1:1000).
The subcellular distribution of ataxin-1 was assessed in stably treated for 45 min with 14 U of shrimp alkaline phosphatase at 37C.
The untreated sample was also incubated at 37C. The treated andtransfected CHO cells by immunostaining as previously described
(Skinner et al., 1997). Cells were plated onto coverslips and stained untreated samples were run in duplicate on a 3%–8% Tris-acetate
polyacrylamide gel (Invitrogen). Following electrophoresis and48 hr later with either M5 (anti-FLAG, 1:200, Sigma) or with 11750
(anti-ataxin-1, 1:200). To determine the frequency of inclusion forma- transfer to nitrocellulose membrane (Protran, Schleicher and
Schuell), the membrane was subjected to autoradiography. Upontion in tissue culture cells, 200 transfected cells from each experi-
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completion of autoradiography, one replicate was probed with Assessment of Motor Ability Using the Rotarod
The accelerating rotarod apparatus was used to assess motor abilityPN1168 (1:1000) while the other was probed with 11750 (1:5000).
as previously described (Clark et al., 1997). The mice were given
four trials per day for four consecutive days. On each day between
Immunohistochemical Staining of Mouse Cerebellum trials, the mice were given a 10 min rest. During a trial the rod
Immunohistochemical staining of mouse cerebellum was performed accelerated from 4 to 40 rpm over the first 5 min and maintained a
as previously described (Klement et al., 1998). Immunohisto- speed of 40 rpm for the remainder of the test. The test lasted until
chemistry was performed on 5 m microtome sections from paraf- the mouse fell from the rod or 10 min had expired, whichever came
fin-embedded brains. After rehydration, epitopes were unmasked first. Data from the A776 mice and nontransgenic littermates were
by steaming for 10 min in pH 6.0 citrate buffer. Staining was carried compared to historical data from B05 ataxin-1[82Q] animals (Clark
out using the ABC Elite kit (Vector). The sections were blocked for et al., 1997). Statistical analyses were performed using a Student’s
20 min in normal serum, incubated overnight at 4C (11750, 1:10,000 t test.
or PN1168, 1:1,000), washed briefly, and incubated for 30 min at
room temperature with biotinylated anti-rabbit secondary antibody. Acknowledgments
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